Contribute Try STAT+ Today

WASHINGTON — In 2000, the Food and Drug Administration approved just three cancer drugs. Last year, even with the agency laser-focused on the coronavirus pandemic, much of its staff teleworking, the agency still approved a record-breaking 17 different cancer therapies — more than in any other category.

That’s the legacy of FDA drug center chief Janet Woodcock.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I headed the Biometric Research Program at the National Cancer Institute for many years and had the opportunity to see a few clinical scientists who had a big impact on the development of effective new drugs for patients with cancer. Dr. Janet Woodcock is one of those individuals. The successes of cancer drug development since about 2005 has been the envy of translational scientists in most other areas of medicine. Unfortunately, most do not understand why we have so many effective new cancer drugs. The main reason is the discovery that cancer is mostly caused by “somatic” (non-inherited) mutations that disrupt the normal organ homeostasis and permit growths to become tumors. The new drugs have been developed to inhibit the de-regulating effect of the mutation. These mutations serve as biomarkers for the selection of patients for clinical trials. This discovery made cancer drug development and evaluation more complex but also more rational and scientifically based rather than just developing DNA toxins in un-selected groups of patients. Dr. Woodcock, with her FDA colleague Dr. Richard Pazdur led the transition to this new paradigm. They provided leadership to the academic community and pharmaceutical industry in this new approach to candidate development and evaluation. Individuals who say that the increase in productivity of cancer drug development is at the expense of approval of numerous poor drugs are incorrect and misleading. Individuals who fault the approval of drugs which have dramatic effects on tumor control although they in themselves may not prolong survival have a simple minded understanding of cancer biology.

Comments are closed.